Compliant Access to Medicines Not Available in Your Country —When Patients Need Them Most

Ikris Pharma Network enables regulated access to specialty, unlicensed, and hard-to-source medicines through the Named Patient Program (NPP) across Europe, including Bulgaria. We support physicians, hospitals, and healthcare providers in accessing critical therapies that are not yet available locally, ensuring compliant sourcing, complete documentation, and reliable delivery. Operating under EU Good Distribution Practice (GDP) standards, we ensure every step—from sourcing to delivery—meets strict European regulatory requirements.

Your Questions Matter—Let's Find the Right Solution Together

+93 Afghanistan

+355 Albania

+213 Algeria

+1-684 American Samoa

+376 Andorra

+244 Angola

+1-264 Anguilla

+672 Antarctica

+1-268 Antigua and Barbuda

+54 Argentina

+374 Armenia

+297 Aruba

+61 Australia

+43 Austria

+994 Azerbaijan

+1-242 Bahamas

+973 Bahrain

+880 Bangladesh

+1-246 Barbados

+375 Belarus

+32 Belgium

+501 Belize

+229 Benin

+1-441 Bermuda

+975 Bhutan

+591 Bolivia

+387 Bosnia and Herzegovina

+267 Botswana

+55 Brazil

+246 British Indian Ocean Territory

+1-284 British Virgin Islands

+673 Brunei

+359 Bulgaria

+226 Burkina Faso

+257 Burundi

+855 Cambodia

+237 Cameroon

+1 Canada

+238 Cape Verde

+1-345 Cayman Islands

+236 Central African Republic

+235 Chad

+56 Chile

+86 China

+61 Christmas Island

+61 Cocos Islands

+57 Colombia

+269 Comoros

+682 Cook Islands

+506 Costa Rica

+385 Croatia

+53 Cuba

+599 Curacao

+357 Cyprus

+420 Czech Republic

+243 DR Congo

+45 Denmark

+253 Djibouti

+1-767 Dominica

+1-809 Dominican Republic

+670 East Timor

+593 Ecuador

+20 Egypt

+503 El Salvador

+240 Equatorial Guinea

+291 Eritrea

+372 Estonia

+251 Ethiopia

+500 Falkland Islands

+298 Faroe Islands

+679 Fiji

+358 Finland

+33 France

+689 French Polynesia

+241 Gabon

+220 Gambia

+995 Georgia

+49 Germany

+233 Ghana

+350 Gibraltar

+30 Greece

+299 Greenland

+1-473 Grenada

+1-671 Guam

+502 Guatemala

+224 Guinea

+245 Guinea-Bissau

+592 Guyana

+509 Haiti

+504 Honduras

+852 Hong Kong

+36 Hungary

+354 Iceland

+91 India

+62 Indonesia

+98 Iran

+964 Iraq

+353 Ireland

+972 Israel

+39 Italy

+225 Ivory Coast

+1-876 Jamaica

+81 Japan

+962 Jordan

+7 Kazakhstan

+254 Kenya

+686 Kiribati

+383 Kosovo

+965 Kuwait

+996 Kyrgyzstan

+856 Laos

+371 Latvia

+961 Lebanon

+266 Lesotho

+231 Liberia

+218 Libya

+423 Liechtenstein

+370 Lithuania

+352 Luxembourg

+853 Macau

+389 Macedonia

+261 Madagascar

+265 Malawi

+60 Malaysia

+960 Maldives

+223 Mali

+356 Malta

+692 Marshall Islands

+222 Mauritania

+230 Mauritius

+262 Mayotte

+52 Mexico

+691 Micronesia

+373 Moldova

+377 Monaco

+976 Mongolia

+382 Montenegro

+1-664 Montserrat

+212 Morocco

+258 Mozambique

+95 Myanmar

+264 Namibia

+674 Nauru

+977 Nepal

+31 Netherlands

+687 New Caledonia

+64 New Zealand

+505 Nicaragua

+227 Niger

+234 Nigeria

+683 Niue

+850 North Korea

+1-670 Northern Mariana Islands

+47 Norway

+968 Oman

+92 Pakistan

+680 Palau

+970 Palestine

+507 Panama

+675 Papua New Guinea

+595 Paraguay

+51 Peru

+63 Philippines

+48 Poland

+351 Portugal

+1-787 Puerto Rico

+974 Qatar

+242 Republic of the Congo

+262 Reunion

+40 Romania

+7 Russia

+250 Rwanda

+1-869 Saint Kitts and Nevis

+1-758 Saint Lucia

+1-784 Saint Vincent and the Grenadines

+685 Samoa

+378 San Marino

+239 Sao Tome and Principe

+966 Saudi Arabia

+221 Senegal

+381 Serbia

+248 Seychelles

+232 Sierra Leone

+65 Singapore

+1-721 Sint Maarten

+421 Slovakia

+386 Slovenia

+677 Solomon Islands

+252 Somalia

+27 South Africa

+82 South Korea

+211 South Sudan

+34 Spain

+94 Sri Lanka

+249 Sudan

+597 Suriname

+268 Swaziland

+46 Sweden

+41 Switzerland

+963 Syria

+886 Taiwan

+992 Tajikistan

+255 Tanzania

+66 Thailand

+228 Togo

+676 Tonga

+1-868 Trinidad and Tobago

+216 Tunisia

+90 Turkey

+993 Turkmenistan

+1-649 Turks and Caicos Islands

+688 Tuvalu

+1-340 U.S. Virgin Islands

+256 Uganda

+380 Ukraine

+971 United Arab Emirates

+44 United Kingdom

+1 United States

+598 Uruguay

+998 Uzbekistan

+678 Vanuatu

+379 Vatican

+58 Venezuela

+84 Vietnam

+681 Wallis and Futuna

+212 Western Sahara

+967 Yemen

+260 Zambia

+263 Zimbabwe

What is a Named Patient Program (NPP)?

A Named Patient Program (NPP), also known as a Managed Access Program, is a regulatory pathway in Europe that allows physicians to access medicines not yet authorized or commercially available in their country for individual patients, based on medical need and national regulatory approval.

Access is physician-led and patient-specific
Medicines must be prescribed based on clinical need
Supply is permitted under controlled and compliant conditions
Each request is subject to national authority approval

When is NPP Used?

Named Patient Programs are typically used when:

The medicine is not available in the patient's country
There are no suitable treatment alternatives
The patient has a life-threatening or serious condition
The patient is not eligible for clinical trials
Existing therapies are ineffective or unavailable

Who Can Request Access?

The treating physician must initiate requests
Access is granted for individual patients only
Patients cannot independently request medicines under NPP

All requests are reviewed in accordance with national regulatory frameworks in Europe.

Types of Medicines Accessible Through NPP

NPP enables access to medicines that are:

Approved in regulated markets (EU, US, UK, Japan)
Not yet launched in the patient's country
Temporarily unavailable due to shortages

How the Named Patient Program Process Works

Physician Request

The treating physician submits a patient-specific request.

Regulatory Review

National authorities evaluate and approve access.

Global Sourcing

Medicines are sourced from regulated markets.

Documentation & Compliance

Full regulatory documentation and traceability ensured.

Secure Delivery

GDP-compliant, temperature-controlled delivery to the healthcare provider.

Why Choose Ikris Pharma Network for the Named Patient Program in Europe?

Authentic Medicine Access

Sourced through a trusted global network, ensuring product authenticity and full compliance with EU GDP standards.

Regulatory Assurance

Aligned with EU and national regulatory frameworks, including Bulgaria.

Controlled Logistics

Advanced cold-chain management for temperature-sensitive therapies, ensuring product integrity from source to delivery.

Seamless Coordination

Dedicated experts managing every step—from sourcing and documentation to delivery—ensuring a smooth and reliable experience.

Therapeutic Areas Covered

We Support Access to Medicines Across

Oncology Rare Diseases Neurology Immunology Critical Care And more

Frequently Asked Questions

How can I access medicines not available in Europe? +

Medicines can be accessed through the Named Patient Program (NPP) with a valid physician prescription and regulatory approval.

Is it legal to import medicines through NPP in Europe? +

Yes, access is permitted under European and national regulatory frameworks when proper documentation and approvals are in place.

Can patients in Bulgaria access medicines through NPP? +

Yes, physicians in Bulgaria can request access to medicines not available locally, subject to national regulatory approval and compliance requirements.

How long does the NPP process take in Europe? +

Timelines vary depending on documentation and approvals, but access is typically arranged within a few days to weeks.

Who can request medicines under NPP? +

Only licensed physicians can initiate requests for individual patients under the Named Patient Program.